KR20160023692A - 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도 - Google Patents

소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도 Download PDF

Info

Publication number
KR20160023692A
KR20160023692A KR1020157035921A KR20157035921A KR20160023692A KR 20160023692 A KR20160023692 A KR 20160023692A KR 1020157035921 A KR1020157035921 A KR 1020157035921A KR 20157035921 A KR20157035921 A KR 20157035921A KR 20160023692 A KR20160023692 A KR 20160023692A
Authority
KR
South Korea
Prior art keywords
cream
administered
ointment
therapeutically effective
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157035921A
Other languages
English (en)
Korean (ko)
Inventor
샤오밍 장
에드워드 에프. 슈니퍼
앤드류 제이. 펄먼
제임스 더블유. 래리크
Original Assignee
타이거캣 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by 타이거캣 파마, 인크. filed Critical 타이거캣 파마, 인크.
Publication of KR20160023692A publication Critical patent/KR20160023692A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157035921A 2013-06-24 2014-06-24 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도 Ceased KR20160023692A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
US13/925,509 2013-06-24
US61/838,784 2013-06-24
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (1)

Publication Number Publication Date
KR20160023692A true KR20160023692A (ko) 2016-03-03

Family

ID=51230173

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157035921A Ceased KR20160023692A (ko) 2013-06-24 2014-06-24 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도

Country Status (13)

Country Link
EP (1) EP3013336A1 (https=)
JP (2) JP2016523260A (https=)
KR (1) KR20160023692A (https=)
CN (1) CN105473138A (https=)
AU (2) AU2014302694B2 (https=)
BR (1) BR112015031724A2 (https=)
CA (1) CA2915474A1 (https=)
HK (1) HK1223820A1 (https=)
IL (1) IL243189A0 (https=)
MX (2) MX366728B (https=)
PH (2) PH12015502777A1 (https=)
RU (1) RU2666219C2 (https=)
WO (1) WO2014209962A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
KR102424837B1 (ko) 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 아프레피탄트의 에멀젼 제형
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
EP3411013A1 (en) * 2016-02-01 2018-12-12 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
EP3478283A4 (en) * 2016-06-29 2020-07-22 Menlo Therapeutics Inc. USE OF NEUROKININ-1 ANTAGONISTS IN THE TREATMENT OF A VARIETY OF PRURITIUS CONDITIONS
AU2018331267B2 (en) * 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
SG11202006782YA (en) * 2018-01-31 2020-08-28 Twi Pharmaceuticals Inc Topical formulations comprising tofacitinib
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
WO2007008564A1 (en) 2005-07-11 2007-01-18 Merck & Co., Inc. Process for making hydroisoindoline tachykinin receptor antagonists
ATE511842T1 (de) 2005-10-04 2011-06-15 Merck Sharp & Dohme Kombinationstherapie zur behandlung von erhöhter miktionsfrequenz, akutem harndrang und inkontinenz
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
US20100209496A1 (en) 2006-09-06 2010-08-19 Eleni Dokou Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20090270477A1 (en) 2006-11-02 2009-10-29 Kuethe Jeffrey T Polymorphs of a hydroisoindoline tachykinin receptor antagonist
AU2008233232A1 (en) 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Also Published As

Publication number Publication date
AU2014302694B2 (en) 2019-10-17
MX366728B (es) 2019-07-22
AU2020200259A1 (en) 2020-02-06
MX2019008643A (es) 2019-09-10
CA2915474A1 (en) 2014-12-31
CN105473138A (zh) 2016-04-06
RU2015154037A (ru) 2017-07-28
MX2015017763A (es) 2016-06-21
AU2014302694A1 (en) 2016-01-07
JP2016523260A (ja) 2016-08-08
IL243189A0 (en) 2016-02-29
HK1223820A1 (zh) 2017-08-11
WO2014209962A1 (en) 2014-12-31
EP3013336A1 (en) 2016-05-04
PH12020500255A1 (en) 2021-02-22
JP2019142960A (ja) 2019-08-29
RU2666219C2 (ru) 2018-09-06
PH12015502777A1 (en) 2016-03-21
BR112015031724A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
US10702499B2 (en) Use of NK-1 receptor antagonists in pruritus
KR20160023692A (ko) 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도
US11026920B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
EP3829572A1 (en) Use of neurokinin-1 antagonists to treat chronic pruritus
US20200121695A1 (en) Compositions and methods for treating itch, skin inflammation, and pruritus
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
WO2007102571A1 (ja) 機能性脳疾患治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190624

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200908

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210614

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200908

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I